Oryzon Genomics announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I/II trial with iadademstat plus immune...
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...
Read moreOryzon Genomics, S.A. announces that it has obtained the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation, and has consequently been registered in the Public Registry of INNOVAT...
Read moreyzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the fourth quar...
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...
Read moreOryzon Genomics today announced that it will host a virtual KOL event to review and discuss the topline results from the Phase IIb PORTICO study evaluating vafidemstat in Borderline Personality Disord...
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced topline results from the Pha...
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...
Read moreOryzon Genomics S.A. se complace en compartir que, de acuerdo al ranking publicado por la Unión Europea, se encuentra entre las 1000 empresas europeas con mayor inversión en I+D, en concreto en la p...
Read moreThe Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selectiv...
Read moreFunding provided by Nice & Green SA, a Swiss private investor, of €8 million in two tranches of €4 million each, plus optional additional tranches of up to €5 million each to be executed in the ...
Read moreOryzon Genomics, S.A. today announced Last Patient Last Visit in its ongoing Phase IIb PORTICO trial, investigating vafidemstat’s efficacy in Borderline Personality Disorder (BPD). Multiple primary ...
Read more